Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT05891080 Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT05891080
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • The person must be willing and able to sign the consent form agreeing to take part in the trial.
  • The person must be 18 years of age or older.
  • The person must have a confirmed diagnosis of non-small cell lung cancer (a type of lung cancer), based on a tissue or cell sample taken by needle, and the cancer must be at a specific advanced stage (stage IIIB or IIIC) confirmed by imaging scans such as CT or PET-CT.
  • The person must have a good general level of physical functioning, rated as fully active or able to carry out light work (confirm with trial site for exact scoring details).
  • The person must have a life expectancy of at least 12 weeks.
  • The person must have at least one area of cancer that can be measured on scans, according to standard measurement rules used in cancer trials.
  • The person must have other major organs (such as the liver, kidneys, and blood system) working well enough to participate.
  • The person must have lung function that is strong enough to tolerate surgery.
  • The cancer must not have spread to other parts of the body.
  • Women who could become pregnant must agree to use effective contraception throughout the study and for at least 120 days after the last dose of chemotherapy or the study drug (whichever comes later), and must have a negative pregnancy test within 7 days before joining the trial.
  • Men who have not had sterilisation must agree to use effective contraception throughout the study and for at least 120 days after the last dose of chemotherapy or the study drug (whichever comes later).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have already received any systemic cancer treatment for a thymic epithelial tumour (a type of tumour in the chest), including surgery, radiotherapy, chemotherapy, targeted therapy, or experimental treatments.
  • People who have any unstable serious health condition, such as an active infection, uncontrolled high blood pressure, unstable or recent chest pain (angina starting within the last three months), moderate-to-severe heart failure, a heart attack within the past six months, a serious heart rhythm problem requiring medication, or significant liver, kidney, or metabolic disease.
  • People who have an active or suspected autoimmune disease (where the immune system attacks the body), or an autoimmune condition related to cancer that requires ongoing treatment.
  • People who are known to be allergic to the study drug or any of its ingredients.
  • People who currently have interstitial lung disease (a condition causing scarring or inflammation in the lungs).
  • People who have active hepatitis B, hepatitis C, or HIV.
  • Women who are pregnant or breastfeeding.
  • People who have a neurological or psychiatric condition that would prevent them from cooperating with the trial.
  • People who are already taking part in another treatment clinical trial.
  • People who the trial researchers consider unsuitable for the trial for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026

Contact this trial

Principal Investigator: Peng Zhang, PhD, Shanghai Pulmonary Hospital, Shanghai, China

Phone: 02165115006

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Registry
ClinicalTrials.gov
Start date
1 July 2023
Est. completion
1 July 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

Pathologic complete response (PCR) rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov